<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129531</url>
  </required_header>
  <id_info>
    <org_study_id>214868-002</org_study_id>
    <nct_id>NCT01129531</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic
      neuralgia (PHN) - nerve pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Average Pain Intensity Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Participants rated the severity of their daily pain in the previous 7 days using a 10 point scale where 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area of Spontaneous Pain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>A tracing of the area of spontaneous pain was made and sent to an independent central reading center for measurement. The area of spontaneous pain was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area of Allodynia</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>A tracing of the area of allodynia (pain to touch) was made and sent to an independent central reading center for measurement. The area of allodynia was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Evoked Pain Score in the Area of Allodynia</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Participants were asked to rate the unpleasantness (pain to touch) after 3 brush strokes in the area of allodynia on a 100 point scale where 0=no pain to 100=worst pain imaginable. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Neuralgia, Postherpetic</condition>
  <arm_group>
    <arm_group_label>AGN-214868 3.25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-214868 16.25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-214868</intervention_name>
    <description>AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.</description>
    <arm_group_label>AGN-214868 3.25 μg</arm_group_label>
    <arm_group_label>AGN-214868 16.25 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to AGN-214868</intervention_name>
    <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months
             after onset of herpes zoster skin rash

        Exclusion Criteria:

          -  Female patients with reproductive potential

          -  Active herpes zoster skin rash

          -  Current or anticipated treatment with acupuncture, TNS, or steroids

          -  Current or anticipated use of topical analgesic agents with PHN

          -  Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>September 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <disposition_first_submitted>October 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 26, 2012</disposition_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were two Treatment Cycles in this study 12 weeks apart. In Treatment Cycle 1 participants were randomized to AGN-214868 3.25 μg, AGN-214868 16.25 μg or Placebo. In Treatment Cycle 2 participants were re-randomized to AGN-214868 3.25 μg, AGN-214868 16.25 μg or Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AGN-214868 3.25 μg</title>
          <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
        </group>
        <group group_id="P2">
          <title>AGN-214868 16.25 μg</title>
          <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Cycle 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94">Participants who completed Treatment Cycle 1 were re-randomized.</participants>
                <participants group_id="P2" count="95">Participants who completed Treatment Cycle 1 were re-randomized.</participants>
                <participants group_id="P3" count="79">Participants who completed Treatment Cycle 1 were re-randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AGN-214868 3.25 μg</title>
          <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
        </group>
        <group group_id="B2">
          <title>AGN-214868 16.25 μg</title>
          <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to &lt; 40 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to &lt; 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt; 75 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Average Pain Intensity Score at Week 12</title>
        <description>Participants rated the severity of their daily pain in the previous 7 days using a 10 point scale where 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-214868 3.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
          </group>
          <group group_id="O2">
            <title>AGN-214868 16.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Pain Intensity Score at Week 12</title>
          <description>Participants rated the severity of their daily pain in the previous 7 days using a 10 point scale where 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.</description>
          <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.248"/>
                    <measurement group_id="O2" value="6.04" spread="1.324"/>
                    <measurement group_id="O3" value="6.05" spread="1.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.876"/>
                    <measurement group_id="O2" value="-1.35" spread="1.996"/>
                    <measurement group_id="O3" value="-1.27" spread="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area of Spontaneous Pain</title>
        <description>A tracing of the area of spontaneous pain was made and sent to an independent central reading center for measurement. The area of spontaneous pain was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-214868 3.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
          </group>
          <group group_id="O2">
            <title>AGN-214868 16.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area of Spontaneous Pain</title>
          <description>A tracing of the area of spontaneous pain was made and sent to an independent central reading center for measurement. The area of spontaneous pain was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
          <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.44" spread="51.312"/>
                    <measurement group_id="O2" value="118.17" spread="74.858"/>
                    <measurement group_id="O3" value="98.27" spread="62.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (N=81, 79, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="62.374"/>
                    <measurement group_id="O2" value="-17.18" spread="62.694"/>
                    <measurement group_id="O3" value="-6.13" spread="68.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area of Allodynia</title>
        <description>A tracing of the area of allodynia (pain to touch) was made and sent to an independent central reading center for measurement. The area of allodynia was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-214868 3.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
          </group>
          <group group_id="O2">
            <title>AGN-214868 16.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment. Participants received two treatments 12 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area of Allodynia</title>
          <description>A tracing of the area of allodynia (pain to touch) was made and sent to an independent central reading center for measurement. The area of allodynia was measured in centimeters squared (cm^2) at Baseline and Week 12. A negative change from Baseline indicated improvement.</description>
          <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.28" spread="145.259"/>
                    <measurement group_id="O2" value="195.11" spread="149.355"/>
                    <measurement group_id="O3" value="174.17" spread="134.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (N=81, 79, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.40" spread="89.849"/>
                    <measurement group_id="O2" value="-43.56" spread="107.183"/>
                    <measurement group_id="O3" value="-15.27" spread="116.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Evoked Pain Score in the Area of Allodynia</title>
        <description>Participants were asked to rate the unpleasantness (pain to touch) after 3 brush strokes in the area of allodynia on a 100 point scale where 0=no pain to 100=worst pain imaginable. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-214868 3.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.</description>
          </group>
          <group group_id="O2">
            <title>AGN-214868 16.25 μg</title>
            <description>AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Evoked Pain Score in the Area of Allodynia</title>
          <description>Participants were asked to rate the unpleasantness (pain to touch) after 3 brush strokes in the area of allodynia on a 100 point scale where 0=no pain to 100=worst pain imaginable. A negative change from Baseline indicated improvement.</description>
          <population>Modified intent to treat population included all randomized participants who received treatment and had at least 1 post-baseline pain intensity score.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="22.39"/>
                    <measurement group_id="O2" value="58.4" spread="24.04"/>
                    <measurement group_id="O3" value="60.0" spread="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (N=82, 80, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="25.36"/>
                    <measurement group_id="O2" value="-7.9" spread="28.61"/>
                    <measurement group_id="O3" value="-11.1" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population (all participants who received at least one dose of study medication) was used to calculate the number of participants at risk for Serious Adverse Events and Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>AGN-214868 3.25 μg_Cycle 1</title>
          <description>One treatment of AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg.</description>
        </group>
        <group group_id="E2">
          <title>AGN-214868 16.25 μg_Cycle 1</title>
          <description>One treatment of AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg.</description>
        </group>
        <group group_id="E3">
          <title>Placebo_Cycle 1</title>
          <description>One treatment of Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain.</description>
        </group>
        <group group_id="E4">
          <title>AGN-214868 3.25 μg_ Cycle 2</title>
          <description>One treatment of AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg.</description>
        </group>
        <group group_id="E5">
          <title>AGN-214868 16.25 μg_ Cycle 2</title>
          <description>One treatment of AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg.</description>
        </group>
        <group group_id="E6">
          <title>Placebo_Cycle 2</title>
          <description>One treatment of Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

